CIK 0001676725 · Large accelerated filer
IDEAYA Biosciences, Inc.
Sign in to watch- Ticker
- IDYA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474268251
- Phone
- 650-443-6209
- Business address
- 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $985,397
- in 1 filing, $985K under 10b5-1 plans
Net −$985,397. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-01 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +628 | $4.31 | $3K | 678,515 |
| 2024-02-01 | Hata Yujiro S President and CEO | Sale 10b5-1 | −624 | $45.00 | $28K | 677,891 |
| 2024-02-01 | Hata Yujiro S President and CEO | Sale 10b5-1 | −4 | $45.01 | $180 | 677,887 |
| 2024-02-01 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −628 | 323,826 | ||
| 2024-01-22 | Ruiz Briseno Andres See Remarks | Sale 10b5-1 | −2,000 | $42.03 | $84K | 26,531 |
| 2024-01-16 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +62,739 | $4.31 | $270K | 740,626 |
| 2024-01-16 | Hata Yujiro S President and CEO | Sale 10b5-1 | −62,739 | $40.17 | $2.5M | 677,887 |
| 2024-01-16 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −62,739 | 324,454 | ||
| 2024-01-12 | Ruiz Briseno Andres See Remarks | Sale 10b5-1 | −2,000 | $38.01 | $76K | 28,531 |
| 2024-01-12 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +12,261 | $4.31 | $53K | 690,148 |
| 2024-01-12 | Hata Yujiro S President and CEO | Sale 10b5-1 | −12,261 | $40.04 | $491K | 677,887 |
| 2024-01-12 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,261 | 387,193 | ||
| 2023-12-18 | Throne Jason Chief Legal Officer | Option exercise 10b5-1 | +10,000 | $7.01 | $70K | 10,000 |
| 2023-12-18 | Throne Jason Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 48,420 | ||
| 2023-12-15 | Throne Jason Chief Legal Officer | Option exercise 10b5-1 | +10,000 | $13.34 | $133K | 10,000 |
| 2023-12-15 | Throne Jason Chief Legal Officer | Sale 10b5-1 | −10,000 | $35.04 | $350K | 0 |
| 2023-12-15 | Throne Jason Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 47,610 | ||
| 2023-12-15 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +75,000 | $4.31 | $323K | 752,887 |
| 2023-12-15 | Hata Yujiro S President and CEO | Sale 10b5-1 | −75,000 | $35.03 | $2.6M | 677,887 |
| 2023-12-15 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −75,000 | 399,454 |
Page 5 of 10 · 186 trades